The main obstacle to curing HIV is the presence of latent proviruses in the bodies of infected patients. The partial success of reactivation therapies suggests that the genomic context of integrated proviruses can interfere with treatment. Here we developed a method called Barcoded HIV ensembles (B-HIVE) to map the chromosomal locations of thousands of individual proviruses while tracking their transcriptional activities in an infected cell population. B-HIVE revealed that, in Jurkat cells, the expression of HIV is strongest close to endogenous enhancers. The insertion site also affects the response to latency-reversing agents, because we found that phytohemagglutinin and vorinostat reactivated proviruses inserted at distinct genomic locations. From these results, we propose that combinations of drugs targeting all areas of the genome will be most effective. Overall, our data suggest that the insertion context of HIV is a critical determinant of the viral response to reactivation therapies.
a r t i c l e s
The development of a treatment for HIV was a turning point in AIDS therapy. Current antiretroviral therapy (ART) suppresses HIV replication to undetectable levels in the plasma. However, some infected cells do not respond to ART, and HIV rapidly rebounds when the treatment is interrupted [1] [2] [3] [4] . The existence of a viral reservoir escaping ART is the major hurdle toward the development of a cure for HIV.
Latent infections of resting CD4 + T lymphocytes are an important component of the treatment-resistant HIV reservoir. Because HIV is transcriptionally silent in these cells, the viruses are invisible to antiviral drugs and to the immune system. Recent research efforts have been geared toward purging the reservoir through reactivation therapies 5 . The principle of these therapies is to maintain patients under ART while treating them with additional drugs, so-called latency-reversing agents, to force the expression of the provirus and consequently render the infected cells susceptible to clearance via the immune system or cytopathic effects.
One main question is how to estimate the efficiency of this strategy in vivo 6 . Viral outgrowth assays yield an estimate of the reservoir size at 0.1-10 cells with a latent infection per million resting CD4 + T lymphocytes 6, 7 . However, these assays provide only a minimal approximation of the frequency of latently infected cells. In contrast, PCR-based methods may overestimate the purgeable reservoir, because they cannot distinguish between replication-competent proviruses and defective or hypermutated proviruses. Moreover, replication-competent proviruses have variable propensities for reactivation. Thus, there is an 'inducible' reservoir composed of viruses that can be reactivated and a 'noninducible' reservoir composed of viruses that cannot be reactivated 8 . Approximately 10% of the noninducible viruses are replication competent 8 . It is still unknown how these viruses are maintained in a silent state, thus indicating that a critical element to allow understanding of HIV latency is lacking.
It has been known since the 1930s that the position of a gene has a critical influence on its expression. When X-ray mutagenesis made it possible to induce chromosomal rearrangements, some genes were observed to become silent when they were translocated near the centromere 9 . This phenomenon, collectively known as 'position effects' was later explained by the roles of histones in transcription. Post-translational modifications of histone tails, typically found at centromeres, can recruit repressors and shut down the expression of a given gene, even if its sequence is unchanged 10 . Position effects occur not only in pericentromeric heterochromatin but also in the rest of the genome. For instance, it has long been observed that transgenes are silenced in ways that depend on their insertion sites 11 . More recently, genome-wide assays, such as thousands of reporters integrated in parallel (TRIP), have revealed that transgenes have similar expression in similar chromatin contexts 12 . However, how the context modifies gene expression has not yet been elucidated. For instance, whether the histone marks on chromosome arms function in a similar manner as the histone marks in pericentromeric heterochromatin remains an open question. In summary, the genomic context of a gene plays a major role in gene expression, but the forces at play are largely unknown.
The above findings suggest that the insertion context may influence the expression of HIV. This notion is supported by experimental data from cell lines, showing that the long terminal repeat (LTR) promoter is sensitive to the local chromatin environment 13 and that latent proviruses are often found near heterochromatin 14 . Interestingly, the insertion of HIV in the human genome is nonrandom. The provirus preferentially integrates in active genes and gene-rich chromosomes 15, 16 . It has recently been shown that this pattern corresponds to loci in physical proximity to the nuclear pores 17 , but it is unclear whether the distribution of insertion sites in the human genome 4 8 VOLUME 24 NUMBER 1 JANUARY 2017 nature structural & molecular biology a r t i c l e s represents an evolutionary optimum or an accident. Nonetheless, there is some evidence that HIV latency may be induced by the chromatin context of the insertion site.
In contrast, the potential role of the insertion site in reactivation therapies has not been addressed. For instance, the first drug used in clinical trials for reactivation therapy is a histone deacetylase (HDAC) inhibitor 18 . This strategy relies on the assumption that chromatin is a key component of HIV latency, but it disregards the fact that HDACs target only a subset of the genome 19 . It is thus doubtful that HDAC inhibitors will have the same effect on all latent proviruses, independently of their insertion site. Moreover, many genes are not activated after blocking of HDACs 19 , so HDAC inhibitors are expected to be ineffective when the provirus is silenced through alternative mechanisms. Overall, the possibility that the failures of reactivation therapy are due to position effects has received little consideration. The reason for this gap is the lack of technologies to study the role of the genomic context in HIV reactivation. More generally, it is important to know whether a latency-reversing agent reactivates only a subset of the latent proviruses, but this knowledge is presently impossible to gain because virions are indistinguishable.
Here we addressed this lack of knowledge by developing B-HIVE technology to track the expression of individual HIV proviruses in a heterogeneous cell population. The strategy involves insertion of DNA barcodes into the genome of recombinant HIV and use of these barcodes to identify all the transcripts produced by a provirus. Using B-HIVE, we found that the expression of HIV depends on the insertion site, thus confirming that the provirus is sensitive to position effects. B-HIVE further revealed that expression hotspots do not coincide with integration hotspots but instead coincide with promoters and enhancers in the host cell. In contrast, latent proviruses are typically found far away from promoters and enhancers. Finally, B-HIVE revealed that different latency-reversing agents activate different subsets of latent proviruses. These results have important implications for reactivation therapy because they suggest that cocktails of drugs with complementary spectra should be developed instead of drugs with synergistic interactions. In summary, our work provides a novel high-throughput technology to study HIV latency and to assay latency-reversing agents.
RESULTS

Principle of B-HIVE
To determine how the local sequence context influences HIV integration, latency and response to drugs, we developed B-HIVE, a genomewide method to map insert-specific expression across thousands of integrated viruses. B-HIVE is inspired by TRIP 12 , a genome-wide method to study position effects. Briefly, the principle of B-HIVE a r t i c l e s involves tagging individual HIV genomes with a unique barcode of 20 nt to track the viral transcripts produced by each provirus of the infected cell population ( Fig. 1 and Supplementary Fig. 1 ). The barcodes are randomly generated during the library preparation (Online Methods and Supplementary Fig. 1 ), and their sequence is unknown until the analysis stage. They can nonetheless be used as universal identifiers because the complexity of the library is sufficiently high that the probability of two proviruses sharing the same barcode is negligible (Online Methods). We used a 4.6-kb minimal HIV construct containing the tat transcriptional activator and a GFP-Nef-encoding fusion gene (Fig. 1a) . This construct has been shown to recapitulate the initial phase of the HIV infection and to spontaneously enter latency in cultured cells 14 . We generated a barcoded HIV library with over one million distinct barcodes and obtained infectious pseudotype particles (HIV BCD ) by cotransfection with a VSV-G expression plasmid (Fig. 1b) . We titrated viral stocks by using the TZM-bl indicator cell line 20 and infected Jurkat cells with a viral inoculum at a multiplicity of infection (MOI) of approximately 0.5. The efficiency of HIV BCD infections was comparable to that of the nonbarcoded pseudotypes ( Supplementary  Fig. 2 ), thus indicating that barcodes do not disable the viruses.
HIV BCD -infected GFP(+) Jurkat cells were sorted by flow cytometry and used to establish a pool of 20,000 infected founder cells (Fig. 1c ). This cell pool was then expanded in culture so that each founder cell produced a clone with identical proviruses. The purpose of this . Proviruses close to enhancers are more expressed than those in intergenic regions (Rep1, 2.2-fold, P = 9.6 × 10 −5 by two-sided Wilcoxon rank-sum test; n = 308 B-HIVE measurements; Rep2, 2.4-fold, P = 2.6 10 −8 by two-sided Wilcoxon rank-sum test; n = 325).
5 0 VOLUME 24 NUMBER 1 JANUARY 2017 nature structural & molecular biology a r t i c l e s approach is three-fold. First, it ensures that every cell in the founder population is infected with at least one active virus. Second, the bottleneck in the founder pool decreases the chances that two viruses have the same barcode. Third, the LTR-driven GFP expression allows identification of latency events on the basis of loss of fluorescence (described below). We then mapped the integrated proviruses by inverse PCR 21, 22 followed by high-throughput sequencing (Fig. 1d ). This step also revealed the sequences of the barcodes ( Fig. 1b and Supplementary Fig. 3 ). We assayed the expression of individual proviruses by measuring the abundance of the barcodes in the RNA pool compared with the DNA pool of the population (Fig. 1e) . This normalization to copy number is essential because founder cells may not divide at the same rate. The combined information reveals the expression landscape of individual proviruses inserted at distinct genomic locations.
Barcoded viruses have wild-type insertion patterns
HIV has a characteristic nonrandom insertion pattern 15, 16 . In T cells, HIV preferentially targets active genes and gene-rich chromosomes.
To analyze whether the barcoded viruses follow the same trend, we carried out two independent infections of barcoded viruses in Jurkat cells. We recovered 1,245 and 1,227 HIV insertion sites in each independent infection, which together recapitulated the known features of HIV integration. The chromosomal distribution of integrated HIV BCD for the two independent infections showed a clear enrichment on chromosomes 16, 17 and 19 ( Fig. 2a) . These results are in agreement with those from a previous study that has analyzed the global distribution of HIV insertions in human chromosomes 17 .
In addition, chromosomes X and Y are targeted less frequently than autosomes because Jurkat cells have two copies of each autosome but only one copy of each sex chromosome. The insertion biases were highly reproducible among independent infections (Fig. 2b) . The insertion rate was approximately three times higher than average on chromosomes 17 and 19 and approximately two times higher than average on chromosome 16. We determined the insertion biases of barcoded proviruses in five genomic features of Jurkat cells: active genes, inactive genes, active promoters, enhancers and intergenic regions (Online Methods and Fig. 2c ). The insertion rates in active genes and enhancers were 3-fold and 2.4-fold higher than expected, respectively. In contrast, insertion rates in inactive genes and intergenic regions were five-fold and four-fold lower than expected, respectively. A preference for active genes and regions bearing enhancer marks is a well-known feature of HIV 15, 23 . In summary, the barcoded viruses showed the same global integration pattern as that of wild-type HIV.
Proximity to enhancers affects HIV expression
During the growth period after fluorescence-activated cell sorting (FACS), Jurkat cells lost fluorescence, and the levels stabilized at approximately 40% (Fig. 1c) . At that point, the expression in the population was at steady state. We measured the individual expression of mapped proviruses by taking the ratio of barcode counts in the RNA pool versus the DNA pool ( Fig. 1e) and measured the expression of 889 and 966 proviruses in each independent infection, respectively (Supplementary Data Set 1). In the other cases, the barcodes were missing from either the RNA or the DNA pool, so we considered the data to be unreliable. The measurements of HIV BCD expression were accurate, as shown by the reproducibility between different RT-PCR runs (Fig. 3a) . We also confirmed the precision of the measurement through template-switch RT-qPCR on selected barcodes ( Supplementary Fig. 4) . Interestingly, the expression levels spanned more than four orders of magnitude. In B-HIVE, the sequencing power is dedicated to the detection of a single transcript, which yields higher resolution than that in typical transcriptome analyses. As a result, low expression levels can be measured with high accuracy.
From the expression profile of HIV on chromosome 19 (featuring the highest density of insertions; Fig. 3b ), we observed that HIV BCD was integrated primarily in gene-rich regions in Jurkat cells, i.e., away from the centromeres. The few proviruses inserted close to the centromeres had lower expression than average. The expression of HIV was nearly constant among chromosomes, and the expression on chromosomes 16, 17 and 19 was not significantly higher (P = 0.48 by one-sided F test with (23, 609) degrees of freedom; n = 633 B-HIVE measurements Fig. 3c ), but proviruses inserted within 5 kb of enhancers had higher expression levels (Fig. 3d) . This result is consistent with the long-standing observation that enhancers do not discriminate between self genes and transgenes and typically activate most genes in their vicinity regardless of gene origin 24 .
Unexpectedly, viruses inserted in active genes, silent genes and intergenic regions had similar expression levels. More generally, when HIV was inserted in a gene, the expression of the provirus showed little correlation with the expression of the host gene (Pearson correlation 0.07, P = 0.005 by two-sided t test; n = 1,546 pairs of RNA-seq gene-expression measurement versus B-HIVE measurement, Supplementary Fig. 5 ). This result indicates that the transcription of HIV is stimulated by endogenous enhancers but not by ongoing transcription. Together, our results show that the insertion context has a predictable influence on HIV expression. 
a r t i c l e s
The insertion site affects the entry into latency Because the insertion site influences HIV expression, we sought to investigate whether it also affects the entry into latency. To address this question, we FACS-sorted the population of Jurkat cells 21 d after infection and separated GFP(+) from GFP(−) subpopulations (Fig. 4a) . The ancestors of all those cells were GFP(+) on day 4 after infection; the loss of fluorescence may be explained by the loss of the virus or by the loss of its expression. The first case corresponds to dead-end infections, i.e., short-lived viruses with a circularized genome that cannot be inserted in the host genome 25 , and the second case corresponds to latency, i.e., a complete shutdown of HIV expression. Other studies have shown that HIV becomes latent early after 26 . Notably, in the experiments presented here, such early latency events would not have been captured in the FACS-sorting on day 4 after infection. Latent proviruses mapped over the whole genome (Fig. 4b) , and the distributions of insertions in the GFP(+) and GFP(−) populations were not significantly different (Fig. 4c) . However, latent insertions mapped further away from enhancers (Fig. 4d) , consistently with our finding that proviruses close to enhancers have higher expression levels. Overall, the insertion site influenced the entry of HIV into latency, but genomic features were poor predictors of the outcome. This finding suggests that latency results from complex relationships between HIV and the host genome.
Latency-reversing agents target distinct proviruses
B-HIVE provides a unique opportunity to pinpoint which proviruses are reactivated by a given reactivation therapy and to quantify the magnitude of the individual response. As a proof of principle, we tested two widely characterized latency-reversing agents 27 . The first, phytohemagglutinin (PHA), elicits a strong activation of T cells and is routinely used for benchmarking; the second, vorinostat (VOR), is an HDAC inhibitor used in clinical trials 28 .
We divided the GFP(−) population into distinct pools and treated them with PHA, with VOR or with DMSO as a control (Fig. 5a) . We also performed a pulse treatment for 24 h followed by a relaxation phase in which the drugs were washed out, then determined the kinetics of the proportion of GFP(+) cells and of the mean fluorescence intensity of the positive cells (Fig. 5b) . After removal of the drugs, HIV expression returned to control values in approximately 10 d. Control quantifications by qPCR and RT-qPCR confirmed that the viruses were still present after 10 d and that their expression was lower ( Fig. 5c and Supplementary Fig. 6 ). An important implication of this result is that a mechanism exists that actively silences latent proviruses. If latency were under the control of a bistable switch, the active state would perpetuate itself after the removal of the drugs, and the proviruses would remain expressed. Instead, silencing takes place again after the drugs are washed out. In the experimental setup depicted in Figure 4a , HIV latency is not an artifact of the infection but instead is a process instructed by the host genome. Do PHA and VOR reactivate different subsets of proviruses, or do they reactivate the same subset to different extents? To answer this question, we measured the expression of individual barcodes in the RNA pool after a 24-h treatment with either drug (Fig. 5d) . The expression of each provirus was very similar between treatments with the same drug, thus showing that the response of the provirus is reproducible. In contrast, we observed substantial variation when comparing the expression of the same provirus treated with different drugs (Fig. 5d and Supplementary Fig. 6 ). That is, the same provirus may respond more strongly to PHA than to VOR, or vice versa. Thus, drugs have different spectra; i.e., they stimulate different subsets of latent proviruses.
These results suggested that it would be possible to identify the proviruses that respond more to one drug or to the other. To this end, we ranked the proviruses as a function of their response to PHA or VOR and formed two groups representing the top 15% of each class (Online Methods). The proviruses that better responded to VOR and those that better responded to PHA had different genomic distributions (Fig. 5e) . In particular, the top 15% of VOR responders were more frequently in the proximity of enhancers than the top 15% of PHA responders. The insertion context thus carries some information about the potential response of a latent provirus to a given drug.
To further characterize the differences between these two classes of proviruses, we measured their genomic distances to chromatin features defined by histone modifications [29] [30] [31] (Fig. 6a) . The top 15% of VOR responders were on average closer to peaks of histone H3 acetylated at K27, trimethylated at K4 and monomethylated at K4; these histone modifications are characteristic marks of active regulatory elements. In contrast, the distances to domains of H3 trimethylated at K36, K79 and K9 were similar between the two groups of proviruses. In summary, proviruses that have a stronger response to VOR than to PHA tend to be located closer to active regulatory elements. Together, our results show that the insertion context of HIV is critical to determine not only the fate of the infection but also the response of the virus to reactivation therapies.
DISCUSSION
Here, we developed B-HIVE technology to study position effects on individual HIV integrations in the human genome (Fig. 1) . We showed that the insertion site affects the expression of the provirus: the chromosome itself has little influence (Fig. 3c) , but proviruses close to the enhancers of the host have higher expression (Fig. 3d) . Hence, latent proviruses are further away from the enhancers of the host genome than nonlatent proviruses (Fig. 4) . Finally, we showed that latency-reversing agents target proviruses inserted at different locations (Fig. 5c) . Overall, these results illustrate the power of barcoding strategies and highlight the importance of the chromosomal context in the development of HIV therapies. Asterisks indicate the significance determined by two-sided Wilcoxon rank-sum tests (K27-acetylated H3 (H3K27ac), ***P = 1.8 × 10 −4 ; K4-trimethylated H3 (H3K4me3), **P = 2.6 × 10 −3 ; K4-monomethylated H3 (H3K4me1), **P = 3.2 × 10 −3 ; n = 98 responders). Box plots were produced with default R options, as in Figure 4 . Data for H3 trimethylated at K36, K79 and K9 are shown. (b) Graphical summary. Latent proviruses that respond more to VOR than to PHA are located closer to regulatory elements (RE). VOR may affect the activity or the targeting of regulatory elements, inducing proviruses inserted in the vicinity.
a r t i c l e s
The strong insertion bias of HIV (Fig. 2) suggests that the virus has evolved to select the most appropriate sites for the infection cycle. Unexpectedly, the attraction toward chromosomes 16, 17 and 19 ( Fig. 2b) is unrelated to HIV expression (Fig. 3d) . Those chromosomes may simply be more accessible to the provirus, either because of the state of their chromatin or because of their proximity to the nuclear pore 17, 32 . However, HIV also tends to target enhancers (Fig. 2c) , where it is expressed at higher levels (Fig. 3d) . If this enrichment has been optimized by natural selection, the potential evolutionary advantages remain speculative.
Previous work on position effect variegation 9 has demonstrated that genomic context influences gene expression. The involvement of chromatin in HIV latency has been described previously 14 , but the theory was not significantly developed before this work. B-HIVE revealed that latent HIV proviruses are depleted near the enhancers of the host (Fig. 4c) . At least two mechanisms may account for this observation. In the first, enhancers may suppress latency by continuously stimulating HIV expression. In the second, silencing mechanisms similar to those occasionally observed in cancer 33 may take place away from enhancers. Our results support the view that HIV can be silenced by the genome of the host (Fig. 5b) , but they do not exclude the first mechanism. Notably, HIV can be latent when it is inserted in the vicinity of enhancers, and the insertion patterns of latent and nonlatent viruses are similar overall (Fig. 4c) . Thus, the decision to enter latency cannot be reduced to a single factor such as the distance to the nearest enhancer.
Only 3% of the viruses were able to be reactivated under maximum stimulation (Fig. 5b) , whereas 12% of the cells were infected (Fig. 5c) . Some positive cells may have escaped detection because the GFP was translated via an internal ribosome entry site (Fig. 1a) , which typically produces moderate amounts of protein. However, this discrepancy also suggests that some latent proviruses are noninducible. Given that latent proviruses tended to map further from enhancers (Fig. 4d) , it is possible that some of them may have been out of reach of VOR, which was most effective on proviruses close to enhancers (Fig. 5e) .
It is still debated whether HIV latency is an evolutionary accident or an intrinsic regulatory process [34] [35] [36] . The evidence that HIV has evolved autonomous mechanisms to shut down its own expression 8, 37, 38 does not exclude a role of chromatin. Autonomous triggers of latency occur early in infection 26 , whereas our experimental setup focuses on latency occurring from 4 d after infection (Fig. 4a) . HIV latency may result from multiple causes. In the near future, it will be important to identify the mechanisms inducing the type of latency that resists current reactivation therapies.
One of the present limitations of B-HIVE is that it is carried out in cellular models. This work was based on experiments performed in vitro, on a single immortalized cell line. It will be important to establish whether our conclusions also hold true in vivo and in the clinic. In its present form, B-HIVE can be applied to track latent infections in animal models, but it cannot be used for clinical samples. For this purpose, in situ barcoding techniques will be required, i.e., methods to barcode latent viruses integrated in patient cells. The steady progress of genome editing via CRISPR-Cas9 may make such technologies available in the future.
Finally, this study provides what is, to our knowledge, the first identification of the differential targets of two drugs used to reactivate HIV. This result naturally raises the question of the mechanism by which the same transcriptional unit, namely HIV, can have different responses to the same treatment. The most likely explanation is that several pathways can silence HIV and that each drug targets a different pathway.
Chromatin silencing mechanisms are poorly understood, and many distinct mechanisms can occur. We suggest that PHA and VOR have distinct effects on human regulatory elements, such that latent HIV inserted in their vicinity would be more activated by VOR (Fig. 6) . More generally, our results suggest that cocktails will be more efficient than single drugs. Previous studies have come to the same conclusion 39 , but here we advocate the use of complementary drugs, which do not need to show synergistic effects. In this respect, B-HIVE should pave the way to the development of combinations of drugs with wide reactivation spectra. In summary, we foresee that the B-HIVE technology and its derivatives will aid in further understanding of the processes governing HIV latency and contribute to the development more efficient eradication strategies.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Cell culture. The human Jurkat T cell line (obtained from the cell collection of the Center for Genomic Regulation, Barcelona) was grown at 37 °C under a 95% air and 5% CO 2 atmosphere, in RPMI 1640 medium (Gibco) supplemented with 10% FBS (Gibco), 1% penicillin-streptomycin (Gibco) and 1% GlutaMAX (100x) (Gibco). Jurkat cells were passaged every 2 d with a 1:5 dilution. HEK 293T cells were grown under the same conditions in Dulbecco's modified Eagle's medium (Gibco). Cells were tested for mycoplasma yearly.
Cloning of HIV-based vector and construction of barcoded HIV library. All infections were carried out in a single-round with a replication-deficient HIV construct derived from plasmid pEV731 (ref. 14) kindly provided by A. Jordan (IBMB, Barcelona). pEV731 is an HIV-based vector encoding the two-exon form of the HIV-1 tat gene and a GFP marker gene under control of the HIV-1 LTR. The sequence of HIV was PCR-amplified from pEV731 and cloned into a 2.9-kb backbone. The resulting vector, pHCC1, was used to prepare libraries of viral vectors by barcoding PCR as detailed below (Supplementary Fig. 1 ).
For barcoding PCR, 100 pg of plasmid pHCC1 was used as template in a Phusion reaction mix (Thermo Fisher Scientific, F530S) in GC buffer with 3% DMSO, with primers GAT431 and GAT432 in the following cycling conditions: 98 °C for 1 min; 98 °C for 20 s, 58 °C for 1 min and 72 °C for 10 min (24 cycles); and 72 °C for 10 min. The template was destroyed by addition of 1 µL 20,000 U/mL DpnI (NEB, R0176S) to the mix and incubation at 37 °C for 30 min. The ends were made complementary and double-stranded by addition of 1 µL 3,000 U/mL T4 DNA polymerase (NEB, M0203S) and incubation at 12 °C for 20 min. The reactions were stopped by addition of 2 µL 0.5 M EDTA and subsequent heat inactivation at 65 °C for 25 min. The products were purified with a QIAquick Gel Extraction Kit (Qiagen) and self-ligated with T4 DNA ligase (Thermo Fisher Scientific, EL0013) with 5% PEG 4000 at 22 °C for 1 h (Supplementary Fig. 1b ). The ligated products (100-200 ng/µL) were precipitated by EtOH and resuspended in 11 µL distilled water. 20 µL ElectroMAX DH10B competent cells (Invitrogen, 18290015) was electroporated with 1 µL ligated products. Sufficient electroporations (typically 2-5) were carried out to obtain a final complexity over 1 million independent clones. 0.01% of the electroporated bacteria were plated on ampicillin-containing medium to estimate the number of clones in the library; the remaining cultures were grown overnight in liquid medium, and the plasmids were extracted the next day.
The complexity of the library estimated from the plating was approximately 1.3 million independent clones. To control the structure of the library (Supplementary Fig. 1c) , ten clones picked from the agar plate were analyzed by PCR (Supplementary Fig. 1d ) and by Sanger sequencing (Supplementary Fig. 1e ). The primers used for barcoding PCR are described in Supplementary Table 1. Transfection and viral Infection. For preparation of viral stocks, two million HEK 293T cells in 10-cm dishes were transfected with 6.5 µg pCMV∆R8.91, 3.5 µg pVSV-G and either 10 µg pEV731 or 10 µg barcoded pHCC1. After 16 h, the medium was replaced. The supernatant was collected 48 and 72 h after transfection. Transfection efficiency was validated on the basis of the percentage of GFP(+) cells determined through FACS analysis. Viral stocks were titrated with the TZM-bl indicator cell line, as described previously 20 . Briefly, five-fold serial dilutions of virus stocks were titrated in quadruplicate in 100 µL culture medium in 96-well culture plates. 10,000 fresh TZM-bl cells were added to each well in 100 µL culture medium. After 48 h, approximately 50 µL of medium was replaced with the Britelite Luc Reporter Gene Assay System reagent (PerkinElmer, 6066769). After a 2-min incubation, 150 µL of cell lysate was transferred to a 96-well solid white plate (Corning-Costar), and luminescence was quantified with a Berthold Centro LB 960 luminometer (Berthold Technologies). The median tissue culture infective dose (TCID 50 ) in luciferase units was calculated with the Spearman and Kärber algorithm 40 .
1 million Jurkat cells in 6-well plates were infected with barcoded viral inocula at an MOI of approximately 0.5. The plates were centrifuged at 1,000g at 32 °C for 90 min. The medium was replaced with 3 mL fresh RPMI 24 h after infection. 48 h after infection, the efficiency of infection was monitored by FACS analysis (Supplementary Fig. 2a) . FACS sorting. Flow cytometry was performed on a FACSCalibur cell sorter (Becton Dickinson). Cells were sorted on day 4 after infection and on day 21 after infection ( Supplementary Fig. 2b-i) with a FACS Aria II-SORP (Becton Dickinson). Before sorting, cells were washed and resuspended in PBS. containing 1 µL 4′,6-diamidino-2-phenylindole (DAPI) at a final concentration of 1 µg/mL. Results shown throughout the manuscript correspond to representative data from experiments repeated at least three times.
Drug treatment for provirus reactivation. GFP(−) Jurkat cells cultured in 10 mL RPMI 1640 medium were treated for 24 h with 2% (v/v) phytohemagglutinin (PHA, Gibco) or with 1 µM vorinostat histone deacetylase inhibitor (VOR, suberoylanilide hydroxamic acid, also known as SAHA, Selleckchem) 41 . DMSO was used as a negative control at a final concentration of 0.1% (v/v).
Nucleic acid isolation and mRNA purification. Genomic DNA and total RNA from infected cell pools were extracted with an AllPrep DNA/RNA Mini Kit (Qiagen, 80284). The mRNA fraction was isolated from total RNA with an Oligotex mRNA Mini Kit (Qiagen, 70022). The mRNAs were eluted in 44 µL of OEB buffer supplied with the kit.
Inverse PCR. 3 µg genomic DNA from infected Jurkat cells was digested with 2 µL 10 U/µL BplI (Thermo Fisher Scientific, ER1311) and 2 µL 5,000 U/mL HpyCH4III (NEB, R0618S) in Tango buffer complemented with 1× SAM in a 50-µL final volume at 37 °C for 3 h. The reaction was heat-inactivated at 65 °C for 20 min. Because BplI and HpyCH4III ends are generally incompatible, fragments were blunt-ended by dilution of the mix in 1× T4 DNA ligase buffer and addition of 3.3 µL 10 mM dNTPs (Thermo Fisher Scientific, R0181), 4.2 µL 3,000 U/mL T4 DNA polymerase (NEB, M0203S), 0.8 µL 5,000 U/mL DNA polymerase I, Klenow fragment (NEB, M0210S) and 4.2 µL 10,000 U/mL T4 polynucleotide kinase (NEB, M0201S) in a 100-µL final volume at 12 °C for 20 min. The reaction was stopped by addition of 2 µL 0.5 M EDTA and subsequent heat inactivation at 65 °C for 20 min. The blunt-end products were diluted in 1 mL T4 DNA ligase buffer, then self-ligated by addition of 2 µL 30 U/µL T4 DNA ligase (Thermo Fisher Scientific, EL0013) and incubation at 16 °C overnight. The ligation reaction was precipitated by EtOH the following day. The pellet was resuspended in 34 µL distilled water. To linearize the ligation products, 2 µL 20,000 U/mL SacI (NEB, R0156S) was added in 40 µL final volume, and the mix was incubated at 37 °C for 3 h. The reaction was then heat-inactivated at 65 °C for 20 min.
For the first round of nested PCR, 8 µL of SacI-digestion products was mixed in 50 µL standard Phusion polymerase reaction mix (Thermo Fisher Scientific, F530S) in GC buffer, with 0.1 µM primers GAT316 and GAT645 (annealing to the Illumina PE1.0 primer and to the U3 region of LTR, respectively). The cycling conditions were as follows: 98 °C for 1 min; 98 °C for 20 s, 65 °C for 1 min and 72 °C for 5 min (10 cycles); and 72 °C for 5 min. For the second round of nested PCR, 10 µL of the products was diluted to 50 µL of standard Phusion polymerase reaction mix in GC buffer with 0.1 µM primer GAT024 (annealing to the Illumina PE1.0 primer) and an indexing primer GAT-int (annealing to the 5′ end of the LTR). The cycling conditions were as follows: 98 °C for 1 min; 98 °C for 20 s, 55 °C for 1 min and 72 °C for 5 min (two cycles); 98 °C for 20 s, 65 °C for 1 min and 72 °C for 5 min (15 cycles); and 72 °C for 5 min. GAT-int primers added the Illumina PE2.0 primer and one of four indices to the amplicons.
PCR products ran as a smear on agarose gel (Supplementary Fig. 3b ). The smears were specific, because they failed to appear when the cells were not infected or were infected with barcode-less viruses, or when no ligation was performed (Supplementary Fig. 3b) . To confirm the structure of the amplicon, clones from a smear obtained after the first round of nested PCR were sequenced (Supplementary Fig. 3c ). The primers used are described in Supplementary  Tables 1 and 2 .
Amplification of RNA and DNA barcodes for high-throughput sequencing. Reverse transcription was performed on 10 µL purified mRNA, to which 1 µL 20 µM reverse primer GAT526 (annealing downstream of the T7 promoter) and 1 µL 10 mM dNTPs (Thermo Fisher Scientific, R0181) were added. RNA was denatured at 95 °C for 1 min and incubated on ice. 8 µL master mix containing 4 µL 5× cDNA synthesis buffer, 1 µL 0.1 M DTT, 1 µL 40 U/µL RNaseOUT, 1 µL DEPC-treated water and 1 µL 15 U/µL ThermoScript (reagents included in the ThermoScript RT-PCR System; Invitrogen, 11145-024) were added to the denatured RNA, and the mix was incubated at 65 °C for 1 h. The reaction was heat-inactivated at 85 °C for 5 min. 5 µL RT product was used as a template in 50 µL standard Phusion polymerase reaction mix (Thermo Fisher Scientific, F530S) in GC buffer, with 1 µM primers GAT024 (annealing on the Illumina PE1.0 primer) and a barcode-specific GAT-bcd-amp primer (annealing on the T7 promoter). The cycling conditions were as follows: 98 °C for 1 min; 98 °C for 20 s, 60 °C for 30 s and 72 °C for 1 min (27 cycles); and 72 °C for 5 min. The GAT-bcd-amp primers added one of 24 indices to the amplicons.
For DNA barcodes, 200 ng genomic DNA from infected Jurkat cells (representing the genome of approximately 20,000 cells) was added to a 50-µL PCR reaction mix identical to that described above for RNA barcodes. The cycling condition were as follows: 98 °C for 1 min; 98 °C for 20 s, 58 °C for 30 s and 72 °C for 1 min (29 cycles); and 72 °C for 5 min. For each condition, at least five tubes were pooled before sequencing (representing the genome of more than 100,000 cells). The primers used here are described in Supplementary Tables 1 and 2. Quantitative PCR (qPCR). qPCR reaction mixes contained either 1 µL of Jurkat genomic DNA diluted 10× or 2 µL of cDNA diluted 10×, 5 µL 2× Power SYBR Green PCR Master Mix (Applied Biosystems, 4367659) and 0.3 µL forward and reverse primers (300 nM final) in a 10-µL final volume. The reactions were carried out in 384-well plates with the following cycling conditions: 95 °C for 10 min; and 95 °C for 15 s, 60 °C for 1.5 min (40 cycles). Primers GAT768 and GAT769 (annealing to GFP) were used to quantify the numbers of viral copies per infected cells. Primers GAT540 and GAT551 (annealing to the 5′ LTR) were used to measure relative RNA expression after the drug treatment. Primers GAT750 and GAT751 (annealing to the human actin gene) and primers GAT1145 and GAT1146 (annealing to HBB, the human hemoglobin subunit beta gene) were used as internal references. The qPCR primers are described in Supplementary Table 1. Sequencing-library preparation. Jurkat mRNA-seq was prepared from 100 ng total RNA with the TruSeq Stranded mRNA Library Prep Kit (Illumina, RS-122-2101) according to the manufacturer's instructions, with a 4.5-min fragmentation time. The quality of each sequencing library was visualized on a Bioanalyzer (Agilent Technologies) and quantified by qPCR with a KAPA library quantification kit (Kapa Biosystems, KK4835). Libraries sequenced in the same lane were pooled together at the final concentration of 4 nM for high-throughput sequencing. Mapping samples were sequenced as 76-bp paired-end reads on a NextSeq sequencer (Illumina); expression and normalization samples were sequenced as 50-bp single reads on a HiSeq2000 sequencer (Illumina) with v3 sequencing chemistry.
Template-switch T7 PCR and confirmation of provirus expression. 2 µg genomic DNA from infected Jurkat cells was used for T7-promoter-driven in vitro transcription to obtain single-stranded RNA (ssRNA). Genomic DNA was first digested in a 20-µL final volume with 2 µL 5,000 U/mL HpyCH4III (NEB, R0618S) at 37 °C for 3 h. The reaction was heat-inactivated at 65 °C for 20 min. To 18 µL products were added 2 µL T7 RNA Polymerase Mix (NEB, E2050S) and 10 µL NTP Buffer Mix (NEB, E2050S). The tubes were incubated at 37 °C overnight. The reactions were stopped by addition of 2 µL 10 mM CaCl 2 (SigmaAldrich, C4901-100G) and 1 µL DNase I (NEB, M0303S) and incubation at 37 °C for 30 min, addition of 2 µL 0.5 M EDTA and heat-inactivation of the DNase I at 70 °C for 10 min. ssRNA products were validated by RT-PCR with primers specific to the minimal HIV 5′-LTR region (Supplementary Fig. 4b) .
The template-switch protocol was modified from a previous report 42 (details in Supplementary Fig. 4a) . A reaction mix containing 2 µL ssRNAs, 1 µL 20 µM reverse primer GAT551 (annealing on the LTR), 1 µL 10 mM dNTPs (Thermo Fisher Scientific, R0181) and 8 µL 100 µM template-switch oligonucleotide GAT997 in a final volume of 12 µL was incubated at 65 °C for 5 min and then placed on ice. 7 µL of master mix containing 4 µL 5× First-Strand Buffer (Invitrogen, 18064-022), 2 µL 0.1 M DTT (Invitrogen, 18064-022) and 1 µL 40 U/µL RNasin Plus RNase Inhibitor (Promega, N2611) was then added to the reaction, and the tubes were incubated at 42 °C for 2 min. 1 µL 200 U/µL SuperScript II reverse transcriptase (Invitrogen, 18064-022) was added, and the tubes were further incubated at 42 °C for 90 min. The reaction was heat-inactivated at 70 °C for 10 min. cDNAs amplified by template switch were validated by PCR, which showed a specific band at 105 bp (Supplementary Fig. 4b ).
To validate B-HIVE expression measurements, qPCR was performed with primers annealing to the selected barcodes (Supplementary Fig. 4c) . The primers used are described in Supplementary Table 1. Estimating the frequency of barcode duplications. The complexity of the barcoded library was estimated at 1.3 million clones. Because 20,000 cells were FACS-sorted after infection, as many barcodes were drawn from a pool of 1.3 million. On average, a barcode was drawn 0.0015 times, thus representing a rare event that is well described by the Poisson distribution. We can thus estimate the probability that a barcode is drawn more than once as Prob (X > 1), where X has a Poisson distribution with a mean of 0.0015. This probability is close to 10 −6 , so duplications are negligible in the conditions of infection used here.
Statistics. All statistical tests were performed with R with default options. Details are provided where appropriate in the main text.
Data and bioinformatic analyses. HIV barcodes were extracted from paired-end reads through an inexact search of the T7 promoter sequence (TATAGTGAGTCGTA), allowing up to three errors (mismatches, insertions and deletions) with Seeq v1.1.2 (http://github.com/ezorita/seeq/). The nucleotides upstream of the hit constitute the barcode (read pairs without hits were discarded). Each barcode was paired with the associated reverse read (containing the insertion site). Sequencing errors in the barcodes were reverted by sequence clustering with Starcode v1.0 (ref. 43) , allowing up to one mismatch, and with the 'message passing' clustering algorithm. The reverse reads were mapped on GRCh37/hg19 with BWA-MEM 0.7.5a-r405 (ref. 44 ) with default parameters and a minimum mapping quality of 20. The sequence of pHCC1 was added to the BWA index to identify sequencing and mapping artifacts (reads mapping to pHCC1 were discarded).
Candidate HIV insertion sites were considered to be identical if they were mapped within 100 bp of each other. We assigned a confidence score to each barcode-locus pair. The score of a pair was defined as the number of reads in which the pair was found, divided by the higher value of either (i) the number of reads in which the barcode was found or (ii) the number of reads in which the insertion site was found. A barcode was assigned to a location if and only if the score for this pair was higher than 0.90, i.e., if >90% of the reads in which the barcode was found were paired to the given location, and >90% of the reads in which the insertion site was found were paired with the given barcode. In practice, the score was recorded as −10 times the log 10 of the complementary probability (similarly to the mapping quality score of the SAM format), so that 10 was the minimum score required to associate a barcode with a location.
RT-PCR on RNA barcodes and PCR on DNA barcodes contained a 4-nt index in the read instead of the standard 6-nt TruSeq Illumina index. We demultiplexed the reads through an inexact search of the constant region of the reads (TATAGTGAGTCGTATTAAAA), allowing up to three errors (mismatches, insertions and deletions) with Seeq. The barcodes corresponded to the nucleotides upstream of the hit, and the indices corresponded to the 4 nt downstream. Barcodes were clustered with Starcode, allowing up to one mismatch, and with the 'message passing' clustering algorithm, and only exact hits to the indices were considered. Reads from different RT-PCR runs were summed for each barcode, and the expression score of a given barcode was computed as the mean-centered log 10 of the ratio between RNA counts and DNA counts.
ChIP-seq reads were mapped on GRCh37/hg19 with BWA-MEM with default parameters and a minimum mapping quality of 20. The targets were identified with Zerone v1.0 (ref. 45 ) with options '-list-output' and '-confidence 0.99' . Enhancers were defined as the enriched H3K27ac regions, yielding approximately 39,000 peaks.
Sequencing reads from Jurkat mRNA were mapped to Ensembl cDNA assembly GRCh37, release 75 with kallisto 46 with options '-single' (single-end mode), '-bias' (sequence bias correction, '-s300' (fragment length 300 nucleotides) and '-l100' (s.d. 100 nucleotides). The counts of the different isoforms were summed, thus generating a total count per gene copy in transcripts per million.
The Jurkat genome was partitioned into five types: active genes, silent genes, active promoters, enhancers and intergenic regions (genes refer to only proteincoding genes). Active genes were defined as the 60% most expressed, and the cutoff between active and inactive genes was set at 0.68 transcripts per million.
